Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis

Psychopharmacology
Javier Vázquez-BourgonBenedicto Crespo-Facorro

Abstract

The use of second-generation antipsychotics (SGA) has been associated with metabolic changes. However, there are differences in the metabolic profile between SGAs. We have previously observed that ziprasidone had a more benign early metabolic profile compared to aripiprazole and quetiapine. However, a long-term follow-up is preferred to detect clinically relevant impairment in metabolic parameters. We aimed to compare the effect of aripiprazole, ziprasidone, and quetiapine on metabolic measures in first-episode non-affective psychosis patients after 1 year of treatment. One hundred and sixty-five drug-naïve patients, suffering from a first episode of non-affective psychosis, were randomly assigned to receive quetiapine, ziprasidone, or aripiprazole. Weight and glycemic/lipid parameters were recorded at baseline and after 1 year of treatment. After 1 year of antipsychotic treatment, we found significant increments in weight, BMI, total cholesterol, LDL-cholesterol, triglycerides, and the triglyceride/HDL index in the sample as a whole. These changes produced a significant rise in the percentage of patients with obesity, hypercholesterolemia, and hypertriglyceridemia. However, when comparing the differential effect of each antips...Continue Reading

References

Apr 8, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·D G DanielM Lakshminarayanan
Aug 2, 2005·The American Journal of Cardiology·Tracey McLaughlinRonald M Krauss
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 4, 2005·The American Journal of Psychiatry·Alan BreierJohn M Kane
Nov 11, 2008·Schizophrenia Research·Rocio Perez-IglesiasBenedicto Crespo-Facorro
Jan 31, 2009·Acta Psychiatrica Scandinavica·S M StahlJ M Meyer
Oct 29, 2009·JAMA : the Journal of the American Medical Association·Christoph U CorrellAnil K Malhotra
Nov 3, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·P MackinP Gallagher
Feb 9, 2011·Archives of General Psychiatry·Debra L Foley, Katherine I Morley
Sep 21, 2011·Annals of General Psychiatry·Fernando ChacónInmaculada Gilaberte
Oct 20, 2011·Nature Reviews. Endocrinology·Marc De HertChristoph U Correll
Dec 15, 2011·Journal of Child and Adolescent Psychopharmacology·Lawrence Maayan, Christoph U Correll
Aug 25, 2016·Neurology and Therapy·Benedicto Crespo-FacorroJacqueline Mayoral-van Son
Nov 5, 2016·Journal of Clinical Psychopharmacology·Qiongzhen LiXiang Yang Zhang
Jan 20, 2017·The Journal of Clinical Psychiatry·Karsten G JensenAnne Katrine Pagsberg
Feb 27, 2017·The Lancet. Psychiatry·Carsten HjorthøjMerete Nordentoft

❮ Previous
Next ❯

Citations

Sep 15, 2018·The International Journal of Neuropsychopharmacology·Marcos Gómez-RevueltaBenedicto Crespo-Facorro
Feb 1, 2019·Journal of Psychopharmacology·Javier Vázquez-BourgonBenedicto Crespo-Facorro
Aug 26, 2020·The International Journal of Neuropsychopharmacology·Javier Vázquez-BourgonBenedicto Crespo-Facorro
Oct 27, 2018·Frontiers in Psychiatry·Danielle A ChipchuraMichael J McCarthy
Dec 24, 2018·Journal of Affective Disorders·Yi-Ju PanLing-Ling Yeh
Dec 31, 2019·Psychoneuroendocrinology·Heather WeiMichael J McCarthy

❮ Previous
Next ❯

Methods Mentioned

BETA
SGA

Software Mentioned

Statistical Package for Social Science ( SPSS )

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here